Internal Medicine, Hematology & Oncology · Santa Monica, CA
NPI
1285817932
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2825 Santa Monica Blvd, Ste. 200
Santa Monica, CA, 90404
Phone (310) 829-5471
Groups this clinician bills Medicare through
Medicare paid, 2024
$259K
11,192 services
Medicare patients, 2024
293
Average age 73
Drug cost, 2024
$1.8M
444 prescriptions
Company payments, 2025
$36K
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Arun S Singh was code 99214 (office e&m - established), 281 times for 128 patients. In total Arun S Singh billed 11,192 services in 82 codes, and Medicare paid $259K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-12-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 281 | 128 | $103.22 | $29K |
| 99232 Hospital E&M - Subsequent | Facility | 190 | 42 | $65.22 | $12K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 173 | 84 | $13.62 | $2,357 |
| 85025 Blood Count | Office | 152 | 75 | $7.61 | $1,157 |
| 99233 Hospital E&M - Subsequent | Facility | 147 | 37 | $98.08 | $14K |
| 80053 Clinical Chemistry | Office | 144 | 77 | $10.35 | $1,490 |
| 96375 Injection Administration | Office | 117 | 12 | $13.35 | $1,562 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 63 | 11 | $0.51 | $31.86 |
| 99205 Office E&M - New | Office | 53 | 53 | $175.92 | $9,324 |
| 99213 Office E&M - Established | Office | 51 | 39 | $76.13 | $3,883 |
| 96413 Chemotherapy Administration | Office | 50 | 13 | $112.74 | $5,637 |
| 99215 Office E&M - Established | Office | 38 | 32 | $147.89 | $5,620 |
| 99239 Hospital Discharge Management | Facility | 37 | 34 | $95.72 | $3,542 |
| 99204 Office E&M - New | Office | 33 | 33 | $127.20 | $4,198 |
| 99223 Hospital E&M - Initial | Facility | 13 | 13 | $143.28 | $1,863 |
By year: 2022 $375K for 13,260 services; 2023 $291K for 15,202 services; 2024 $259K for 11,192 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 152 | 75 | $7.61 | $1,157 |
| 80053 Clinical Chemistry | 144 | 77 | $10.35 | $1,490 |
Medicare prescription drug claims, 2024
In 2024, the drug Arun S Singh prescribed most often to Medicare patients was Imatinib Mesylate, with 74 prescriptions and refills. In total Arun S Singh wrote 444 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Imatinib Mesylate Generic | 74 | 92 | Under 11 | $59K |
| Gleevec Imatinib Mesylate | 24 | 24 | Under 11 | $254K |
| Pazopanib Hcl Generic | 21 | 21 | Under 11 | $177K |
| Imiquimod Generic | 16 | 16 | Under 11 | $295 |
| Ondansetron Odt Ondansetron | 15 | 15 | Under 11 | $207 |
| Ibrance Palbociclib | 13 | 13 | Under 11 | $194K |
| Gabapentin Generic | 13 | 13 | Under 11 | $1,288 |
| Vitrakvi Larotrectinib Sulfate | 13 | 13 | Under 11 | $516K |
| Qinlock Ripretinib | 12 | 12 | Under 11 | $500K |
| Erlotinib Hcl Generic | 12 | 12 | Under 11 | $2,816 |
| Potassium Chloride Generic | 12 | 12 | Under 11 | $290 |
| Meloxicam Generic | 12 | 12 | Under 11 | $82.44 |
Brand drugs: - claims; generic drugs: 342 claims; opioid claims: 28.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Arun S Singh $36K ($36K in general payments such as food, travel and fees and $284 for research) from 7 companies. The largest payer was Daiichi Sankyo Inc. with $23K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.